About the project:
The aim of the project is the development of compounds for the treatment of Alzheimer´s disease (AD). The project will include an approaches of personalized medicine during the development process in the way that novel compounds will be tested in a disease in a dish (DiD) model derived from AD patients.
In the year 2021, we have started to develop new potential drugs against Alzheimer´s disease. There are two different approaches. First, aiming to modify damaged brain signaling, second to enhance the removal of toxic proteins from the brain. These compounds will be studied and characterized in the following years. In order to test those compounds on a suitable model, we have started to develop a model derived directly from the patient. This model will be developed from the patient suffering by the familiar form of the AD. His blood cells will be transformed (differentiated) to the neuronal cells, which will then be used for further testing.
In 2022, we continued to develop new potential Alzheimer’s disease (AD) drugs by thoroughly characterizing the properties of the drugs through laboratory experiments. By compiling this data, we were able to select the most promising compounds to be evaluated on animals in the coming year. We also examined the nature of the disease (mother+daughter) in two pairs of patients. The known type of AD seems to be very rare and we assume that they suffered from other types of dementia other than AD. This (and other aspects described above) somewhat contradicts our intention to develop a so-called disease-in-a-dish model of typical familial AD.
Beneficiary and project partners:
Fakultní nemocnice Hradec Králové
Ústav experimentální medicíny AV ČR, v. v. i.
University of Oslo
The TARIMAD project benefits from a € 1.4 mil. grant from Norway Grants and Technology Agency of the Czech Republic. The project is carried out under the KAPPA funding programme for applied research, experimental development and innovation, managed by the Technology Agency of the Czech Republic.